Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes
Abstract
In addition to glycemic control, the anti-inflammatory effects and protective effect of metformin on sepsis have been reported in animal studies, which may be beneficial for patients with septic shock. Few observational studies have evaluated metformin administration after sepsis or bacteremia; however, these studies did not specifically analyze septic shock or long-term outcomes. Therefore, this study aimed to evaluate the associations between metformin administration after septic shock and the short- and long-term survival in septic shock patients with type 2 diabetes mellitus. This retrospective observational study used data from a prospectively collected sepsis registry. From October 2016 to June 2022, adult septic shock patients with type 2 diabetes mellitus were included in this study. The variable of interest was metformin administration within 48 h after diagnosis of septic shock. The 90-day mortality and 365-day mortality were evaluated as outcomes. A multivariable Cox proportional hazards model was conducted. A total of 320 patients were included in the study. Metformin administration within 48 h after diagnosis of septic shock was associated with lower 90-day mortality (13.0% vs. 39.8%, P < 0.001), 365-day mortality (23.3% vs. 48.3%, P = 0.001), and in-hospital mortality (9.3% vs. 28.6%, P = 0.002) than those who did not administer metformin within 48 h. Metformin administration within 48 h was independently associated with decreased 90-day mortality (adjusted…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.